BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines

被引：0
|
作者：
M. Cuadros
V. Sánchez-Martín
A. Herrera
C. Baliñas
J. Martín-Padrón
L. Boyero
P. Peinado
P. P. Medina
机构：
[1] University of Granada,Department of Biochemistry and Molecular Biology III and Immunology
[2] GENYO,Department of Biochemistry and Molecular Biology I
[3] Centre for Genomics and Oncological Research,undefined
[4] University of Granada,undefined
来源：
Clinical and Translational Oncology | 2017年 / 19卷
关键词：
BRG1; miR-155; Leukemia; Prednisolone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1010 / 1017
页数：7
相关论文
共 50 条
  • [1] Correction to: BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines
    M. Cuadros
    V. Sánchez-Martín
    A. Herrera-Merchan
    C. Baliñas
    J. Martín-Padrón
    L. Boyero
    P. Peinado
    P. P. Medina
    Clinical and Translational Oncology, 2019, 21 (11) : 1580 - 1580
  • [2] Expression of Concern: BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines
    M. Cuadros
    V. Sánchez-Martín
    A. Herrera-Merchan
    C. Baliñas
    J. Martín-Padrón
    L. Boyero
    P. Peinado
    P. P. Medina
    Clinical and Translational Oncology, 2019, 21 (11) : 1581 - 1581
  • [3] BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines (Expression of Concern of Vol 19, Pg 1010, 2017)
    Cuadros, M.
    Sanchez-Martin, V.
    Herrera-Merchan, A.
    Balinas, C.
    Martin-Padron, J.
    Boyero, L.
    Peinado, P.
    Medina, P. P.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (11): : 1581 - 1581
  • [4] BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines (Publication with Expression of Concern. See vol. 21, pg. 1581, 2019)
    Cuadros, M.
    Sanchez-Martin, V.
    Herrera, A.
    Balinas, C.
    Martin-Padron, J.
    Boyero, L.
    Peinado, P.
    Medina, P. P.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (08): : 1010 - 1017
  • [5] BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines (vol 19, pg 1010, 2017) (Publication with Expression of Concern. See vol. 21, pg. 1581, 2019)
    Cuadros, M.
    Sanchez-Martin, V.
    Herrera-Merchan, A.
    Balinas, C.
    Martin-Padron, J.
    Boyero, L.
    Peinado, P.
    Medina, P. P.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (11): : 1580 - 1580
  • [6] Regulation of Human CNS Myeloid Cell Inflammatory Responses by mir-155
    Moore, Craig
    Rao, Vijayaraghava
    Durafourt, Bryce
    Bedell, Barry
    Ludwin, Samuel
    Bar-Or, Amit
    Antel, Jack
    NEUROLOGY, 2013, 80
  • [7] Inhibition of the miR-155 target NIAM phenocopies the growth promoting effect of miR-155 in B-cell lymphoma
    Slezak-Prochazka, Izabella
    Kluiver, Joost
    de Jong, Debora
    Smigielska-Czepiel, Katarzyna
    Kortman, Gertrud
    Winkle, Melanie
    Rutgers, Bea
    Koerts, Jasper
    Visser, Lydia
    Diepstra, Arjan
    Kroesen, Bart-Jan
    van den Berg, Anke
    ONCOTARGET, 2016, 7 (03) : 2391 - 2400
  • [8] MiRNA-155 regulates lymphangiogenesis in natural killer/T-cell lymphoma by targeting BRG1
    Chang, Yu
    Cui, Meng
    Fu, Xiaorui
    Zhang, Lei
    Li, Xin
    Li, Ling
    Wu, Jingjing
    Sun, Zhenchang
    Zhang, Xudong
    Li, Zhaoming
    Nan, Feifei
    Yan, Jiaqin
    Zhang, Mingzhi
    CANCER BIOLOGY & THERAPY, 2019, 20 (01) : 31 - 41
  • [9] Phase 1 Trial of Cobomarsen, an Inhibitor of Mir-155, in Cutaneous T Cell Lymphoma
    Querfeld, Christiane
    Foss, Francine M.
    Kim, Youn H.
    Pinter-Brown, Lauren
    William, Basem M.
    Porcu, Pierluigi
    Pacheco, Theresa
    Haverkos, Bradley M.
    DeSimone, Jennifer
    Guitart, Joan
    Halwani, Ahmad S.
    Eradat, Herbert A.
    Huen, Auris
    Schroeder, Kristin
    Pestano, Linda A.
    Williams, Paul J., Jr.
    Cheronis, Ioanna
    Gordon, Gilad S.
    Escolar, Diana
    Rubin, Paul
    Marshall, William S.
    BLOOD, 2018, 132
  • [10] miR-155 regulates HGAL expression and increases lymphoma cell motility
    Dagan, Liat Nadav
    Jiang, Xiaoyu
    Bhatt, Shruti
    Cubedo, Elena
    Rajewsky, Klaus
    Lossos, Izidore S.
    BLOOD, 2012, 119 (02) : 513 - 520
12345